MR Imaging Biomarker for the Characterization of dynamic metabolic processes in patients with aberrant glucose and/or neurotransmitter metabolism

Conditions: EpilepsyBrain tumors

Registration Number: DRKS00031213

Lead Sponsor: Medizinische Universität Wien

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 60

Inclusion Criteria

Brain tumor patients:
(glucose-avid brain lesions: 5 with cerebral metastases, 5 with lymphomas, 10 high-grade gliomas according to the updated WHO classification 2021) with a Karnofsky performance status =70% who received a routine MRI protocol at 3 T including contrast medium -enhancing agents within two weeks prior to the first study-related measurement but before any biopsy, resection, or radiosurgery occurred. For this pilot study, the group of patients with brain metastases will include distant metastases of all types of primary tumors)
Epilepsy patients:
(Clearly defined epileptogenic lesions in MRI such as malformations of cortical development, vascular malformations, scars, etc., routine clinical examinations including long-term video EEG monitoring, FDG-PET, routine clinical T1/T2-weighted MRI)

Exclusion Criteria

MRI inclusion and exclusion criteria:
- Exclusion of pregnancy
- Exclusion of nursing mothers
- Anamnestic exclusion of a metal implantation (pacemaker, metal heart valves, surgical clips, implanted electronic infusion pumps, tattoos and the like).
- Exclusion of a contrast medium allergy
- Anamnestic exclusion of claustrophobia
- Exclude recent head/brain surgery
- Exclusion of a metabolic disorder (HbA1c>6%)

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is possible to detect metabolic changes in glucose/neurotransmitter metabolism in selected brain pathologies (e.g. brain tumors, epilepsy) with expected metabolic changes.

Secondary Outcome Measures

Name	Time	Method
on-invasive imaging of glucose and neurotransmitter metabolism via time-resolved MRSI is possible using both clinical routine 3T and experimental 7T MR scanners.